Verlies van het reukvermogen is een belangrijk symptoom van chronische rhinosinusitis met neuspoliepen en treft tot wel 90% van de patiënten.1,2 Reukverlies, dat leidt tot een aanzienlijke impact op het dagelijks leven en een psychologische ziektelast3, is een belangrijke indicator van type 2-inflammatie4 en kan het eerste teken zijn van een terugkeer van de ziekte.1,2

<figure class="table" style="width:100%;">
 <table style="background-color:#7A00E6;border-color:#7A00E6;border-style:solid;">
 <tbody>
 <tr>
 <td style="background-color:#7A00E6;border-color:#7A00E6;">
 <h3 style="text-align:center;">Type 2 Inflammatie en reukverlies</h3>
 </td>
 </tr>
 </tbody>
 </table>
</figure>

<ul>
 <li data-list-item-id="ed7e7b3c493cc43fdf71bcc47cd1bf562">Reukverlies is een van de meest impactvolle symptomen van CRSwNP1,2</li>
 <li data-list-item-id="ec907b70d96acc2bd00942277e269b195">Het heeft een impact op de kwaliteit van leven3 van patiënten en kan zelfs na een operatieaanhouden4</li>
 <li data-list-item-id="e3402a7be3c5f583a2d60b85bd4e4e15e">Type 2 inflammatie kan een rol spelen bij het ontstaan van anosmie of hyposmie5</li>
 <li data-list-item-id="ea5746d1f025e50a4872cba10f55320a6">Ongeveer 90% van de CRSwNP-patiënten ervaart reukverlies1</li>
 <li data-list-item-id="e50a8b8b1647df80bb289d202a9cef9de">Anosmie of hyposmie kan een teken zijn van een terugkerende ziekte1,2</li>
 <li data-list-item-id="e276a1154f4b57bdb867760c5d5a33828">De mate van type 2 inflammatie correleert met de ernst van het reukverlies1,2</li>
</ul>

<figure class="table" style="width:100%;">
 <table style="background-color:#7A00E6;border-color:#7A00E6;border-style:solid;">
 <tbody>
 <tr>
 <td style="background-color:#7A00E6;border-color:#7A00E6;">
 <h3 style="text-align:center;">Reukverlies wordt in verband gebracht met type 2 inflammatie5-9</h3>
 </td>
 </tr>
 </tbody>
 </table>
</figure>

<figure class="table" style="width:100%;">
 <table style="background-color:#7A00E6;border-color:#7A00E6;border-style:solid;">
 <tbody>
 <tr>
 <td style="background-color:#7A00E6;border-color:#7A00E6;">
 <h3 style="text-align:center;">Reukverlies vormt een zware last voor CRSwNP-patiënten1,2</h3>
 </td>
 </tr>
 </tbody>
 </table>
</figure>

Verminderde kwaliteit van leven (HR-QoL)1,10

Dagelijkse activiteiten worden beïnvloed3

Depressie, angst, fobie, vermoeidheid, irritatie, enz.3

Invloed op persoonlijke relaties11

Economische last, verminderde productiviteit12

<figure class="table" style="width:100%;">
 <table style="background-color:#7A00E6;border-color:#7A00E6;border-style:solid;">
 <tbody>
 <tr>
 <td style="background-color:#7A00E6;border-color:#7A00E6;">
 <h3 style="text-align:center;">Reukverbetering als maat voor ziektecontrole</h3>
 </td>
 </tr>
 </tbody>
 </table>
</figure>

benadrukken het belang van reukverlies als behandeldoel13-14

bij de klinische beoordeling van CRS1

Is complex en vereist een multidisciplinaire aanpak19-21

Referenties en Afkortingen

Heeft u vragen of wilt u meer weten? Wij zorgen dat u zo snel mogelijk geholpen wordt.

Wij staan klaar

Chronische Rhinosinusitis met Nasale Poliepen (CRSwNP): De verbinding tussen Type 2 Inflammatie en Reukverlies

SPECIALTY-CARE

DUPIXENT

CHRONIC-RHINOSINUSITIS-WITH-NASAL-POLYPS-CRSWNP

RESPIRATORY

<h2>ASCVD is the world's biggest killer.1&nbsp;
 
 To take it on, we need to be nothing less than unstoppable.</h2>
Since PRALUENT*'s (alirocumab) approval by the EMA in 2015,2 to this very day, we have been working collectively with patients and healthcare professionals against ASCVD.
Between unstoppably investigating LDL-C reduction and CV event prevention, constant innovation, and continuous collaboration with healthcare professionals to bridge gaps in lipid management, being unstoppable has taken us far.3-8
But it's only just the start.
*Primary hypercholesterolaemia and mixed dyslipidaemia : Praluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, and in paediatric patients 8 years of age and older with heterozygous familial hypercholesterolaemia (HeFH) as an adjunct to diet: - - in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. Established atherosclerotic cardiovascular disease - Praluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: - - in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Since PRALUENT's first approval, we've been unstoppably generating evidence to better understand its efficacy and safety profile across various ASCVD populations:3-7

<h3>2015-2020 - ODYSSEY phase 3 programme</h3>
The ODYSSEY phase 3 programme - encompassing 11 distinct phase 3 trials - investigated PRALUENT's impact on LDL-C reduction and CV outcomes across high-risk populations.3,10-20

<h3>2020 - SYDNEY device study and CHOICE I</h3>
The SYDNEY device study and CHOICE I trial investigated PRALUENT 300 mg once-monthly in high-risk populations.4,5

<h3>2025 - ODYSSEY post hoc pooled analysis</h3>
The pooled analysis of phase 3 ODYSSEY studies assessed PRALUENT's effect on LDL-C reduction in ASCVD patients who had not yet experienced a first CV event.6

<h3>2026 ongoing - OPTIMUS programme</h3>
Through the OPTIMUS programme, we're continuing to explore treatment approaches in ASCVD management with real-world and simulation studies utilising advanced methodologies.7,9*

*RWE studies can vary substantially in their methodological approaches, which may contribute to heterogeneity or unexpected findings across analyses. Ensuring that key epidemiological principles - such as appropriate time-zero definition, new-user design considerations, handling of open claims data, and assessment of potential time-related biases - are rigorously applied remains essential to generating reliable insights. High-quality RWE therefore depends on robust and methodologically advanced approaches such as propensity score matching and G-computation used in the studies.

<h3>Over the last decade, we've remained committed to the patient and HCP experience by unstoppably innovating.</h3>
In 2016, the PRALUENT 300 mg once-monthly dose was approved in the EU.21 Then, with the release and development of devices like SYDNEY and the Next-Gen pen, PRALUENT became and remains the only PCSK9i with a once-monthly single injection in a pre-filled pen.22*

Through initiatives like the ACS EuroPath programme, we've been unstoppably identifying gaps in LDL-C management and working with cardiologists to help bridge them.8
With surveys conducted in 2018, 2022 and 2024, we've been able to gain insights into how lipid management has changed over the years and where there are still opportunities for improvement.8 By collaborating with cardiologists on dyslipidaemia guideline implementation, we've also shown how enhanced guideline adherence can help improve outcomes for ACS patients.8

<h2>Key findings from our latest ACS EuroPath programme include</h2>

Lipid management of ACS patients has continuously improved from 2018 to 2024.8

Suboptimal LDL-C goal attainment persists, emphasising need for sustained efforts to help improve outcomes for ACS patients.8

Training cardiologists on dyslipidaemia guidelines helped improve outcomes for patients.8

<h3>For over 10 years, we've never paused in making progress against ASCVD</h3>
We've been unstoppably generating evidence. Unstoppably innovating. Unstoppably collaborating with healthcare professionals to help improve outcomes for patients.3-8,22
But it's only just the start.
 
 Here's to the next 10 years being unstoppable against ASCVD.
 
 Are you coming with us?

Indication &amp; dosing information

Referenties

Unstoppable commitment to ASCVD care for over 10 years

GENERAL-MEDICINES

CV-T-CORE

PRALUENT

DYSLIPIDEMIA

CARDIOLOGY

In severe asthma, lung function is significantly impaired, characterized by reduced FEV₁ and a decreased FEV₁/FVC ratio, reflecting persistent airflow obstruction.1
Chronic airway inflammation, together with airway remodeling, contributes to progressive and partly irreversible structural changes2. These alterations play a key role in the long-term decline in lung function observed in this patient population.
From a clinical standpoint, this has substantial implications for disease burden and patient quality of life, including3,4:

<h3 style="text-align:center;">Watch Prof. Guy Brusselle explains how severe asthma impacts lung function and how to monitor it</h3>

ASTHMA

The Importance of Lung Function in Severe Asthma - A Clinical Perspective

<h2>How is Lung Function Measured?</h2>
<figure class="table" style="width:100%;">
 <table style="background-color:#e4e4e4;border-color:#fff;border-style:solid;">
 <tbody>
 <tr>
 <td style="background-color:#e4e4e4;border-color:#fff;padding:15px;">
 <h3>Spirometry is a common technique to measure lung function1</h3>
 </td>
 </tr>
 </tbody>
 </table>
</figure>
<ul>
 <li>On post-bronchodilator (BD) spirometry1,5&nbsp;&nbsp;
 
 - Improvement in FEV1 in patients with reduced pre-BD FEV1 is an indicator of BD responsiveness1
 
 - Reduced FEV1 may suggest airway remodelling5</li>
 <li>FEV1/FVC ratio can be used in conjunction with FEV1 to identify airway obstruction and expiratory airflow limitation1,6</li>
 <li>Low FEV1 is a risk factor for lung function decline1</li>
</ul>

<figure class="table" style="width:100%;">
 <table style="background-color:#23004c;border-color:#fff;border-style:solid;">
 <tbody>
 <tr>
 <td style="background-color:#7A00E6;border-color:#7A00E6;padding:10px;text-align:center;">
 <h3>Did you know?</h3>
 </td>
 </tr>
 <tr>
 <td style="background-color:#23004c;border-color:#23004c;padding:20px;">
 <h3>The declining FEV1 is a key indicator of asthma exacerbation risk</h3>
 </td>
 </tr>
 </tbody>
 </table>
</figure>
Lung function decline is associated with high exacerbation risk, and repeated exacerbation events further reduce FEV1,7,8,9

<h2>Assessing lung function is crucial for optimal asthma management in patients</h2>
Systematic monitoring of lung function is therefore essential in the management of severe asthma. Repeated measurements not only provide insight into disease severity but are also critical for10:
<ul>
 <li>Patient phenotyping</li>
 <li>Evaluation of treatment response</li>
 <li>Optimization and adjustment of therapy, including the use of biologics</li>
</ul>
<figure class="table" style="width:100%;">
 <table style="background-color:#e4e4e4;border-color:#fff;border-style:solid;">
 <tbody>
 <tr>
 <td style="background-color:#e4e4e4;border-color:#fff;padding:15px;">
 <h3>FeNO can help identify patients with asthma at risk of rapid lung function loss9</h3>
 </td>
 </tr>
 </tbody>
 </table>
</figure>

<h3>FeNO is a predictor of accelerated decline in lung function in patients with severe asthma. FeNO≥20 ppb is associated with a relative risk of 1.9 of having an accelerated decline in FEV111*</h3>

As highlighted in GINA guidelines, lung function assessment plays a central role in evidence-based decision-making and the individualization of treatment strategies in patients with severe asthma1.

<h2>FEV1 Improvement as a Key Component of Asthma Remission criteria</h2>
Improvement in FEV1 is increasingly recognized as a fundamental component of asthma remission criteria, as it reflects restoration of lung function beyond symptom control alone. Emerging international consensus statements include FEV1 optimization or normalization among clinical remission criteria, with a commonly proposed threshold of FEV1 ≥ 80% of predicted value12.

<figure class="table" style="width:100%;">
 <table style="background-color:#23004c;border-color:#fff;border-style:solid;">
 <tbody>
 <tr>
 <td style="background-color:#7A00E6;border-color:#7A00E6;padding:10px;text-align:center;">
 <h3>Key messages</h3>
 </td>
 </tr>
 <tr>
 <td style="background-color:#23004c;border-color:#23004c;padding:20px;">
 <h3>Low FEV1 is associated with lung function decline and risk of exacerbations.1,7
 
 The 2026 GINA guidelines recommend periodic assessment of lung function; at least every 1–2 years, but more frequently in patients at higher risk and severe asthma1</h3>
 *95% CI: 7.3–73.2
 </td>
 </tr>
 </tbody>
 </table>
</figure>

Abbreviations &amp; References

Een platform voor beroepsbeoefenaren om betrouwbare en relevante informatie over onze medicijnen en therapieën te vinden.

Welkom bij Campus Sanofi Nederland

OUT-OF-TAXONOMY

Voor uw intercontext, meld u aan bij uw account Sanofi Campus. Geef uw e-mail door aan uw e-mail.

Als u onze eerste e-mail op {email} tot bevestig uw account u kunt hieronder een nieuwe aanvragen. Als je het niet ziet, moet je mogelijk je spammap controleren.

Deze informatie wordt alleen gebruikt om uw account te valideren en wordt niet verspreid.

titel

Title

Korte samenvatting

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

Om u een gepersonaliseerde ervaring te bieden, moet u

Je profiel is onvolledig

De ADCT geeft een indicatie van hoe gecontroleerd het eczeem is. Beantwoord deze 6 eenvoudige vragen met uw patiënt om de ADCT-score te vinden. Het zal de juiste handelwijze aangeven.

Atopische dermatitis, een vorm van eczeem, kan het leven van uw patiënt op meer manieren beïnvloeden dan u weet.

Doe de atopische dermatitis controle test (ADCT)

Geniet van meer exclusieve inhoud{newline}door <a>door u vandaag te registreren</a>

Heb je al een account? <a>Hier inloggen</a>

Best practices voor het optimaliseren van de patiëntenzorg

Krijg een aangepast beeld van de onderwerpen waarin u geïnteresseerd bent, samen met de mogelijkheid om inhoud op te slaan om op een later tijdstip te bekijken of te lezen.

Onbeperkte toegang tot eersteklas inhoud, whitepapers, casestudy's, onderzoekspapers, webinars, training en up-to-date wetenschappelijke medische bronnen.

Gepersonaliseerde inhoud op basis van uw interessegebieden

Maak contact en blijf up-to-date met collega's op uw vakgebied en onderwerpen die u interesseren via gratis evenementen en leidinggevende forums.

Registreer om het volledige artikel te lezen.

Wij respecteren uw privacy en zullen uw informatie niet delen met derden.

Actuele gidsen die speciaal voor patiënten zijn geschreven

Onbeperkte toegang tot de nieuwste patiëntengidsen en bronnen. Deel inhoud met uw patiënten met gebruiksvriendelijke online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Beperkte toegang

Share via {platform} (opens email client)

Cause And Symptoms

Complications

Diagnosis And Treatment

Overview

Prevention

References

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

Normaal gesproken bieden we een schat aan kenis, maar we konden niet vinden waar je naar op zoek bent.

We konden niet vinden wat je zocht

There are no upcoming events

Showing {start}–{end} of {total} events

Event details

Check back later for upcoming events, or browse all available events across therapeutic areas.

There are no events scheduled for this therapeutic area

Something went wrong

Try a different keyword, date range, or venue.

No matching events

Registration information

Success! We've received your request

Sanofi is niet verantwoordelijk voor de inhoud van deze externe website.

U staat op het punt Campus.sanofi/nl te verlaten.

Volg ons:

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus® (nirsevimab-alip) Injection, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

Title should not exceed 100 characters

Enter your title

Sanofi biedt u exclusieve content over onze verschillende therapeutische gebieden op één portal speciaal voor professionals in de gezondheidszorg, inclusief wetenschappelijk nieuws, een lijst met evenementen en tools en diensten voor uw dagelijkse praktijk.

Bevestig uw status

Welcome to ITP Sanofi Campus

De inhoud van deze website is alleen toegankelijk voor geregistreerde gebruikers.

Log in alstublieft

Review the materials in your cart before checkout.

Browse and order materials for your practice.

Filters

Materials

Cart

Checkout

Email verificatie

U ziet een voorbeeld van de portal. Wis uw cookies (bijvoorbeeld door uw browservenster te sluiten) om terug te gaan naar de openbare modus.

We hebben onze privacyverklaring bijgewerkt om je gegevens beter te beschermen en je ervaring te verbeteren. Neem even de tijd om de wijzigingen door te nemen door <privacyNewTab>hier te klikken</privacyNewTab>. Uw privacy is belangrijk voor ons. Klik op doorgaan om te bevestigen dat u de nieuwe privacyverklaring hebt gelezen.

Update van de privacyverklaring

Communicatie toestemming

My consents

Password

Confirm password

{resultsCount, plural, one {resultaat} other {resultaten}}

Log in om toegang te krijgen tot de resultaten

U moet inloggen op uw account om toegang te krijgen tot medische inhoud.

Inloggen

Registreer in minder dan 1 minuut om toegang te krijgen tot de resultaten

U verlaat nu het Sanofi inhoudsgedeelte van onze site en komt in het inhoudsgedeelte voor extern medisch bibliografisch zoeken.

U verlaat nu het externe medische bibliografische zoekgedeelte van onze site en komt in het inhoudsgedeelte van Sanofi.

You are about to leave the T1D website

Welcome to the T1D Sanofi Website

Geniet van meer exclusieve inhouddoor door u vandaag te registreren

Welkom bij Campus Sanofi Nederland

Wetenschappelijk nieuws

Chronische Rhinosinusitis met Nasale Poliepen (CRSwNP): De verbinding tussen Type 2 Inflammatie en Reukverlies

Unstoppable commitment to ASCVD care for over 10 years

The Importance of Lung Function in Severe Asthma - A Clinical Perspective